Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Regulators Synergize Horizon Scanning Efforts

New Network Will Focus On Identifying Potentially Disruptive Technologies

Executive Summary

The International Coalition of Medicines Regulatory Authorities has established an innovation network to identify emerging technologies and develop internationally acceptable approaches for their regulation.

You may also be interested in...

Canada Consults On Customized Rules For Approving Unique Drugs, Devices

Health Canada is inviting suggestions from stakeholders as it works on implementing a flexible approach for authorizing complex and novel health products. The regulator also draws up new clinical trial rules.

EU Initiative Flags Up Challenging Products For Regulators

A new EU group is keeping a bird's eye view on new innovative medicinal products being brought before member states’ innovation offices, and has flagged up "emerging challenges" and "interesting cases" identified throughout 2017 that need further discussion at the level of the EU medicines network.

‘Decentralized Clinical Trials 2.0’ On The Horizon

The remarkable shift towards decentralized clinical trials in the last three years is a testament to how this patient-centric approach of doing research has the potential to solve multiple issues such as time, cost and low participation rates. In this first segment of a two-part article, Pink Sheet looks at how innovation in this sector has just begun and we can expect more action ahead. 


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts